Therapeutic efficacy and safety of monotherapy Alfuprost® MR 10 mg/day in clinical practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Corresponding author: Novikov A.I. - Ph.D., MD, professor at the Department of Urology of FGBOU VO North-Western State Medical University named after I.I. Mechnikov, Head of the Department of Oncourology of State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care, Saint Petersburg, Russia; novikov_urol@mail.ru Introduction. Alpha-blockers are the first-line therapy for men with BPH/LUTS. They have similar efficiency, but different uroselectivity. Therefore, when choosing α-blockers, their safety and adverse events should be taken into account. Aim. To evaluate the efficiency and safety of using Alfuprost® MR 10 mg/day for 12 months in clinical practice. Materials and methods. A total of 55 men aged 55-80 years with BPH/ LUTS were included in the study, which was carried out on the basis of 6 outpatient clinics in St. Petersburg from June 2020 to September 2021. Along with standard methods, the examination included an assessment of male sexual function, hemodynamic parameters, and satisfaction with the treatment of patients and physicians using the Likert scale. The follow-up scheme included 7 visits (every 60±5 days) and lasted 12 months. Results. After 2 months of therapy with Alfuprost® MR, a significant decrease in the number of patients complaining of pain was observed. The proportion of patients with urgency and difficulty with urinating decreased by 50% and 30%, respectively. By the end of the treatment, the total IPSS score decreased by 1.9 times and averaged 9.98 points, the quality of life improved by 2.5 points, the average maximum urine flow rate significantly increased by 1.4 times, reaching 17.4 ml/sec, and the post-void residual volume decreased to 12.5 ml (3.8 times). By the last visit, there was a decrease in prostate volume by 4.3%. Moreover, the proportion of patients with an initial level of total PSA 2.5-4 ng/ml decreased by 25.4%. The level of PSA after treatment less than 2.5 ng/ml was seen in 70.9% of cases. All patients were satisfied with the treatment after 2 months, as well as investigators at visit 5. There was a significant improvement in all components of the sexual function, especially erectile function. In addition, there were no significant changes in ejaculation. Conclusion. Long-term therapy with Alfuprost® MR 10 mg/day has high therapeutic efficacy and safety in elderly patients with LUTS/BPH, regardless of comorbidities.

Full Text

Restricted Access

About the authors

A. I Novikov

State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care; North-Western State Medical University named after I.I. Mechnikov

Email: novikov_urol@mail.ru
Ph.D., MD, professor at the Department of Urology; Head of the Department of Oncourology

E. S Shpilenya

North-Western State Medical University named after I.I. Mechnikov

Ph.D., MD, professor at the Department of Urology

References

  1. Calogero A.E., Burgio G, Condorelli R.A., Cannarella R. et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. The Aging Male. 2019;22(1):12-19
  2. Аполихин О.И., Сивков А.В., Бешлиев Д.А. Анализ урологической заболеваемости в Российской Федерации в 2002-2009 годах, по данным официальной статистики. Экспериментальная и клиническая урология. 2011;1:4-10
  3. Просянников М.Ю., Цой А.А., Мадыкин Ю.Ю. Организация трехуровневой системы медицинской помощи в урологии. М.: Изд-во «Уромедиа», 2017. 122 с
  4. Шпиленя Е.С., Бурлака О.О., Пешехонов К.С., Шабулдов К.В. Оказание неотложной помощи при острой задержке мочеиспускания у мужчин. Современная лечебная тактика, противоречия и перспективы. Скорая медицинская помощь. 2019;20(1):69-79
  5. Наумов А.В., Алексеев И.Д., Будылев С.А. Болезни стареющих мужчин: в фокусе предстательная железа. Врач скорой помощи. 2011;6:31-39
  6. Корнеев И.А., Алексеева Т.А., Коган М.И., Пушкарь Д.Ю. Эпидемиология расстройств мочеиспускания у мужчин Российской Федерации. Урология. 2016;2:70-75
  7. Chartier-Kastler E, Chapple C.R. LUTS/BPH in clinical practice: the importance of nocturia and quality of sleep. BJU international. 2006;98:3-8.
  8. Caine M., Perlbert S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554.
  9. Lepor H., Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol. 1984;132(6):1226-1229.
  10. Djavan B. et al. State of the art on the efficasy and tolerability of a1 adrenoreceptor antagonists in patients with LUTS. BPH. Urology, 2004.
  11. Tatemichi S., et al. Yakugaku Zasshi. 2006;12:209-216. Data on file, Watson Laboratories, Inc. KMD-0005 Study Report.
  12. Jin-Qui Yuan, Chen Mao, et al.Comparitive Tffectiveness and safety of monodrug therapies for LUTS associated with Benign Prostatic Hyperplasia. Medicine. 2015;94(27).
  13. Yu Z-J, Yan H-L, Xu F-H, Chao H-C, DengL-H, XuX-D, Huang J-B and Zeng T (2020) Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Front. Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658.
  14. Oelke M. et al. Cardiovascular and ocular safety of a1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13(9):1187-1197.
  15. Духанин А.С. Фармакологические аспекты терапии доброкачественной гиперплазии предстательной железы адреноблокаторами. Эффективная фармакотерапия. 2018;2:38-46
  16. Mottet N., Bressolle F., Delmas V., et al. Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol. 2003;44:101-105.
  17. Roehrborn С., Rosen R. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical interventions in aging. 2008;3(3):511-524.
  18. Nickel J.C., et al. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.Int J Clin Pract, 2008;62:1547.
  19. Mari A., Antonelli A., Cindolo L. et al. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis Ther Adv Urol. Urology 2021 Apr 12;13:1756287221993283.
  20. Park J., Lee Y.J., Lee J.W., Yoo T.K.Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study. Korean Journal of Urology. 2015;56(3):233.
  21. Baron M., Cornu J.N. Medical Aspects ofthe Treatment of LUTS/BPH: Alpha-Blockers. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Academic Press, 2018. P. 177-188.
  22. Barbalias G.A. Why Alpha-Blockers in Prostatitis? Eur Urol. 2003;2(2):27-29.
  23. Спивак Л.Г. Диагностика и терапия хронического простатита и связанных с ним нарушений фертильности с использованием альфа1-адреноблокаторов. Дисс. канд. мед. наук. М., 2005. 170 c
  24. Chlosta P., Drewa T., Kaplan S. А-blockade, apoptosis, and prostate shrinkage: How are they related? Growth 2013;6:189-194.
  25. Minutoli L. et al. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.Int J Mol Sci. 2016;17:1311. doi: 10.3390/ijms17081311.
  26. Abrams P., Feneley R. The significance of the symptoms associated with bladder outflow obstruction. Urol.Int. 1978;3:33.
  27. Officers A. Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies